Tenofovir
Active nucleotide analog released from tenofovir alafenamide (TAF, cathepsin A) or tenofovir disoproxil fumarate (TDF, esterases) prodrugs. Intracellularly phosphorylated to active tenofovir diphosphate. Moderate renal handling; accumulates in kidney tubules.
Pharmacokinetic model
A route-level PK model for tenofovir is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- NRTI active (extracellular)
- Half-life
- 17 h
- Reference dose range
- 1–8 mg (single dose)
- Suggested cadence
- custom (shown daily)
- Validated against
- 300 mg oral — Cmax 0.30 mg/L at 1 h
Documented interactions
-
watch
Doravirine (Pifeltro) + Tenofovir
Doravirine (Pifeltro) and Tenofovir both push the hiv reverse transcriptase in the same direction.
-
watch
Efavirenz (Sustiva) + Tenofovir
Efavirenz (Sustiva) and Tenofovir both push the hiv reverse transcriptase in the same direction.
-
watch
Rilpivirine (RPV / Edurant) + Tenofovir
Rilpivirine (RPV / Edurant) and Tenofovir both push the hiv reverse transcriptase in the same direction.
Serum checks 3 modeled interaction pairings for tenofovir across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.